$BMRA
BIOMERICA INC Stock $bmra

$bmra Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000151316223000067 Filed on April 14, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$1.108M	$1.111M	$7.661M
YoY Change	-79.1%	-85.49%	111.03%
Cost Of Revenue	$1.079M	$991.2K	$5.987M
YoY Change	-76.94%	-83.45%	63.14%
Gross Profit	$28.81K	$120.3K	$1.673M
YoY Change	-95.36%	-92.81%	-4283.05%
Gross Profit Margin	2.6%	10.82%	21.84%
Selling, General & Admin	$1.496M	$1.379M	$1.324M
YoY Change	-28.11%	4.21%	3.42%
% of Gross Profit	5191.77%	1146.9%	79.11%
Research & Development	$368.9K	$392.0K	$457.0K
YoY Change	24.18%	-14.22%	-18.39%
% of Gross Profit	1280.32%	325.93%	27.31%
Depreciation & Amortization	$18.36K	$15.00K	$33.60K
YoY Change	-92.25%	-55.36%	12.0%
% of Gross Profit	63.73%	12.47%	2.01%
Operating Expenses	$1.865M	$1.771M	$1.781M
YoY Change	-21.58%	-0.52%	-3.22%
Operating Profit	-$1.836M	-$1.651M	-$107.5K
YoY Change	4.52%	1435.97%	-94.28%
Interest Expense	$55.63K	$36.09K	$6.020K
YoY Change	706.23%	499.5%	-84.95%
% of Operating Profit
Other Income/Expense, Net	$1.000K	$36.09K
YoY Change
Pretax Income	-$1.779M	-$1.615M	-$101.5K
YoY Change	1.7%	1491.53%	-94.48%
Income Tax	$13.01K	$34.78K	$2.690K
% Of Pretax Income
Net Earnings	-$1.792M	-$1.650M	-$104.2K
YoY Change	1.89%	1483.81%	-94.34%
Net Earnings / Revenue	-161.72%	-148.44%	-1.36%
Basic Earnings Per Share		-$0.12	-$0.01
Diluted Earnings Per Share	-$0.11	-$0.12	-$8.125K
COMMON SHARES
Basic Shares Outstanding	16.82M shares	13.48M shares	12.82M shares
Diluted Shares Outstanding		13.48M shares	12.82M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.719M	$3.345M	$10.17M
YoY Change	64.26%	-67.12%	93.05%
Cash & Equivalents	$9.719M	$3.345M	$10.17M
Short-Term Investments
Other Short-Term Assets	$300.0K	$318.5K	$667.1K
YoY Change	-6.33%	-52.27%	-13.36%
Inventory	$2.056M	$2.064M	$3.231M
Prepaid Expenses
Receivables	$722.0K	$754.6K	$1.159M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.80M	$6.482M	$15.23M
YoY Change	35.74%	-57.44%	41.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$213.0K	$227.6K	$1.631M
YoY Change	-0.47%	-86.05%	-11.84%
Goodwill
YoY Change
Intangibles	$165.0K	$154.6K
YoY Change	-2.94%
Long-Term Investments	$165.0K	$165.3K	$165.3K
YoY Change	-0.19%	0.0%	-2.75%
Other Assets	$79.00K	$78.60K	$147.0K
YoY Change	-17.35%	-46.52%	-47.51%
Total Long-Term Assets	$1.657M	$1.728M	$2.329M
YoY Change	-14.88%	-25.82%	-9.37%
TOTAL ASSETS
Total Short-Term Assets	$12.80M	$6.482M	$15.23M
Total Long-Term Assets	$1.657M	$1.728M	$2.329M
Total Assets	$14.45M	$8.210M	$17.56M
YoY Change	27.08%	-53.25%	31.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$344.0K	$387.2K	$2.609M
YoY Change	-53.26%	-85.16%	243.27%
Accrued Expenses	$548.0K	$869.9K	$876.0K
YoY Change	132.2%	-0.7%	46.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.945M	$1.395M	$6.698M
YoY Change	-3.3%	-79.17%	396.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$785.0K	$828.9K	$1.105M
YoY Change	-24.39%	-24.96%	-21.1%
Total Long-Term Liabilities	$785.0K	$828.9K	$1.105M
YoY Change	-24.39%	-24.96%	-21.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.945M	$1.395M	$6.698M
Total Long-Term Liabilities	$785.0K	$828.9K	$1.105M
Total Liabilities	$2.730M	$2.224M	$7.803M
YoY Change	-10.48%	-71.5%	183.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$42.00M	-$40.40M
YoY Change	19.74%
Common Stock	$1.346M	$1.079M
YoY Change	30.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.72M	$5.986M	$9.758M
YoY Change
Total Liabilities & Shareholders Equity	$14.45M	$8.210M	$17.56M
YoY Change	27.08%	-53.25%	31.54%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.792M	-$1.650M	-$104.2K
YoY Change	1.89%	1483.81%	-94.34%
Depreciation, Depletion And Amortization	$18.36K	$15.00K	$33.60K
YoY Change	-92.25%	-55.36%	12.0%
Cash From Operating Activities	-$962.7K	-$1.725M	$2.358M
YoY Change	-77.39%	-173.14%	-273.4%
INVESTING ACTIVITIES
Capital Expenditures	$14.14K	$5.760K	-$18.85K
YoY Change	-158.05%	-130.56%	-81.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$14.14K	-$5.760K	-$18.85K
YoY Change	-41.95%	-69.44%	-81.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$637.7K
YoY Change			-39.84%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.350M	24.75K	637.7K
YoY Change	19149.9%	-96.12%	-39.84%
NET CHANGE
Cash From Operating Activities	-962.7K	-1.725M	2.358M
Cash From Investing Activities	-14.14K	-5.760K	-18.85K
Cash From Financing Activities	7.350M	24.75K	637.7K
Net Change In Cash	6.373M	-1.706M	2.977M
YoY Change	-250.17%	-157.3%	-844.3%
FREE CASH FLOW
Cash From Operating Activities	-$962.7K	-$1.725M	$2.358M
Capital Expenditures	$14.14K	$5.760K	-$18.85K
Free Cash Flow	-$976.8K	-$1.731M	$2.377M
YoY Change	-76.92%	-172.8%	-288.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-02-28
	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	154638	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	169516	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78598	usd
	dei	Entity File Number EntityFileNumber	001-37863
	dei	Entity Registrant Name EntityRegistrantName	BIOMERICA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-2645573
	dei	Entity Address Address Line1 EntityAddressAddressLine1	17571 Von Karman Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92614
	dei	City Area Code CityAreaCode	949
	dei	Local Phone Number LocalPhoneNumber	645-2111
	dei	Security12b Title Security12bTitle	COMMON STOCK, PAR VALUE $0.08
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Trading Symbol TradingSymbol	BMRA
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16821646	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3345212	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5916983	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	17432	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	153231	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	754559	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	773818	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	807576	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	845549	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2064152	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2416447	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	318448	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	320283	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	6482371	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9427531	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1316268	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1305360	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	227589	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214487	usd
CY2023Q1	bmra	Accumulated Amortization Right Of Use Assets AccumulatedAmortizationRightOfUseAssets	927077	usd
CY2022Q2	bmra	Accumulated Amortization Right Of Use Assets AccumulatedAmortizationRightOfUseAssets	724802	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1101648	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1301834	usd
CY2023Q1	us-gaap	Investments Investments	165324	usd
CY2022Q2	us-gaap	Investments Investments	165324	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27383	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18994	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95588	usd
CY2023Q1	us-gaap	Assets Assets	8210168	usd
CY2022Q2	us-gaap	Assets Assets	11374280	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	387228	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	972372	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	520457	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	646944	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	138013	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	50670	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	349410	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	341296	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1395108	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2011282	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	828944	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1038284	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2224052	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3049566	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13488313	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13488313	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12867924	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12867924	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1079065	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	1029432	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45443164	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42446597	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-110911	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-73936	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40425202	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35077379	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5986116	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8324714	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8210168	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11374280	usd
CY2023Q1	us-gaap	Revenues Revenues	1111442	usd
CY2022Q1	us-gaap	Revenues Revenues	7660501	usd
	us-gaap	Revenues Revenues	4230792	usd
	us-gaap	Revenues Revenues	13569188	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	991169	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	5987277	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3813599	usd
	us-gaap	Cost Of Revenue CostOfRevenue	11213175	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	120273	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	1673224	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12611760	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1649859	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-104168	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5347823	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2772023	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13481490	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12820481	shares
	us-gaap	Gross Profit GrossProfit	417193	usd
	us-gaap	Gross Profit GrossProfit	2356013	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1379412	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1393619	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4589255	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3817061	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	392031	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	387104	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1215143	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1316581	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1771443	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1780723	usd
	us-gaap	Operating Expenses OperatingExpenses	5804398	usd
	us-gaap	Operating Expenses OperatingExpenses	5133642	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1651170	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-107499	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5387205	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2777629	usd
CY2023Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	36086	usd
CY2022Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	6019	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	77368	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	19740	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1615084	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101480	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5309837	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2757889	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34775	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2688	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37986	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14134	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1649859	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-104168	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5347823	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2772023	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.4
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.4
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13481490	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12820481	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13340958	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12611760	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13340958	shares
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-15498	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2538	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-36975	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-12901	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1665357	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-106706	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5384798	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2784924	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8324714	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13950	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1763568	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-12527	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	303755	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2071876	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8321584	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	65205	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	172914	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-8950	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	318230	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1626088	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7242895	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	24750	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-15498	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	383828	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1649859	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5986116	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	9227023	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3895	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	800710	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-5613	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	319622	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1542581	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	8803056	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30585	usd
CY2021Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	883413	usd
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-4750	usd
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	314397	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-1125274	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8901427	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4695	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	633037	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2538	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	325349	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-104168	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	9757802	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5347823	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2772023	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65640	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	102272	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	135799	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	817122	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-37973	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	270805	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1005813	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	959368	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	202275	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	189696	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-155058	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1113435	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-390268	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	295980	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1835	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	296839	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-16986	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-117171	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-585144	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2025460	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-126487	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	148388	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	87343	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3213052	usd
	bmra	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-203315	usd
	bmra	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-180637	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4511323	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3777046	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	113436	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	63860	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32547	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63860	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-145983	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2014054	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2401734	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	52822	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	84574	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	79155	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	39175	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2040387	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2356335	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-36975	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-12901	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2571771	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5974497	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5916983	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4199311	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3345212	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10173808	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	37986	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	13334	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">NOTE 1: BASIS OF PRESENTATION</span></b></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p><p style="font-size: 11pt; font-family: 'Times New Roman',sans-serif; text-align: justify; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Biomerica, Inc. and its subsidiaries (which includes wholly owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is </span><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </span><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(physicians' offices and over-the-counter (“OTC”) through drugstores and online) </span><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</span><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The </span><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black">Our primary focus is the research, development, commercialization, and in certain cases regulatory approval, of patented, diagnostic-guided therapy (“DGT”) products based on our InFoods® Technology platform that are designed to treat gastrointestinal diseases, such as irritable bowel syndrome (“IBS”), and other inflammatory diseases. These InFoods® based products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. The first product we are launching using the patented InFoods Technology is our InFoods® IBS product which uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping and constipation. Instead of broad and difficult-to-manage dietary restrictions, the InFoods® IBS product works by identifying a patient’s above normal immunoreactivity to specific foods. A food identified as causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. Following the successful completion and positive statistical results from the Company’s InFoods IBS clinical trial (run at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan) which was completed in early calendar 2022, Biomerica received interest from Gastroenterology (“GI”) physicians who would like to order the InFoods IBS test for their patients even prior to the product receiving FDA clearance. As such, we are currently working with key GI physician groups who are interested in offering this product to their patients. Given this, during the third quarter ended February 28, 2023, we worked to set up the InFoods® IBS test to be performed in a Clinical Laboratory Improvement Amendments (“CLIA”) certified, and College of American Pathologists (“CAP”) accredited high-complexity laboratory facility and offered as a laboratory developed test (“LDT”). During the quarter ended February 28, 2023, the CLIA lab completed all validation testing necessary for the InFoods IBS product to be offered as an LDT and, as of quarter end, is now accepting patient samples. We also worked to optimize the process for GI physicians to order the InFoods IBS test, send patient blood samples to the CLIA lab and receive the test results for their patients. We believe ease of order and workflow for physicians, with easy to understand and actionable results for patients, is critical to our success. During the quarter, we also set up customer service and payment systems, along with a dedicated website for patients to receive answers to questions they may have about the test and attain information about how to eliminate a specific food from their diet. This is especially important for foods that are ingredients in common processed foods like milk, eggs and wheat. As of the end of the fiscal third quarter, the product is now available to physicians and their patients.</span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and OTC at Walmart, Amazon, and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations.</span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic, in March 2020 we began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. In fiscal 2022, we generated revenues from the international sale of our COVID-19 antigen tests that use a patient’s nasal fluid sample to detect if the patient is currently infected with the virus. Due to falling demand for such tests, the Company generated 0.4% of our sales during the three months ended February 28, 2023, as compared to 79% of our revenue during the three months ended February 28, 2022.. Further, during the nine months ended February 28, 2023 6% of our sales were generated from our COVID-19 related products, as compared to 80% of our revenue during the nine months ended February 28, 2022. </span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">Our non-COVID-19 products that accounted for approximately 94% and 20% of our revenues during the nine months ended February 28, 2023 and 2022, respectively, are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country’s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black">The unaudited condensed consolidated financial statements herein have been prepared by management pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The accompanying interim unaudited condensed consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended May 31, 2022. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended February 28, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2023. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended May 31, 2022 included in the Company's Annual Report on Form 10-K filed with the SEC on August 29, 2022. Management has evaluated all subsequent events and transactions through the date of filing this report.</span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">ACCOUNTING ESTIMATES</span></b></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical experience with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40400000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3345000	usd
	bmra	Working Capital WorkingCapital	5087000	usd
CY2020Q3	bmra	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	90000000	usd
CY2021Q1	bmra	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	15000000	usd
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9400000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">CONCENTRATION OF CREDIT RISK</span></b></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">The Company’s primary banking partners are Bank of America and Merrill Lynch. The Company maintains cash balances in accounts at financial institutions in excess of amounts insured by federal agencies, as well as substantial cash reserves in investment grade money market accounts and in U.S. treasury bills. <span style="COLOR:black">As of February 28, 2023,</span> the Company had approximately $3,095,000 of uninsured cash. <span style="COLOR:black">The Company does not believe it is exposed to any significant credit risks.</span></span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">For <span style="COLOR:black">the </span>three m<span style="COLOR:black">onths ended February 28, 2023,</span> the Company had one key customer who is located in Asia which accounted <span style="COLOR:black">for 22%</span>. For <span style="COLOR:black">the </span>three m<span style="COLOR:black">onths ended February 28, 2022,</span> the Company had three key customers who are located in Asia and the United States which accounted <span style="COLOR:black">for 79% of net consolidated sales</span>. For <span style="COLOR:black">the </span>nine m<span style="COLOR:black">onths ended February 28, 2023,</span> the Company had one key customer who is located in Asia which accounted <span style="COLOR:black">for 38%</span>. For <span style="COLOR:black">the </span>nine m<span style="COLOR:black">onths ended February 28, 2022,</span> the Company had three key customers who are located in Asia and the United States which accounted <span style="COLOR:black">for 75% of net consolidated sales</span>. </span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p><p style="font-size: 11pt; font-family: 'Times New Roman',sans-serif; text-align: justify; margin: 0in 2.7pt 0in 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total gross receivables on February 28, 2023 and May 31, 2022 were approximately </span><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">$772,000 and $927,000, <span style="color: black;">respectively. On February 28, 2023, the Company had two customers which accounted for a total of 44% of gross receivables. On May 31, 2022 the Company had one key customer </span>which accounted for a total of 50% of gross receivables.</span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black">For the </span><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">three <span style="COLOR:black">months ended February 28, 2023, the</span> Company had two key vendors which accounted for 31% of the purchase of raw materials. <span style="COLOR:black">For the </span>three <span style="COLOR:black">months ended February 28, 2022, the</span> Company had one key vendor which accounted for 92% of the purchase of raw materials.</span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black">For the </span><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">nine months ended <span style="COLOR:black">February 28, 2023, there was no individual vendor that comprised more than 10% of the Company’s purchases.. For the </span>nine months ended <span style="COLOR:black">February 28, 2022, the </span>Company had one key vendor which accounted for 85% of the purchase of raw materials.</span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black">As of February 28, 2023, </span><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">the Company had one key vendor which accounted for 18% of accounts payable. As of May 31, 2022, the Company had two key vendors which accounted for 69%.</span></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; LINE-HEIGHT:normal"> </p>
CY2023Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3095000	usd
CY2023Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	772000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	927000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	782000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	2872000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	17000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	153000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	465000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	318000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	320000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	808000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	846000	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1714000	usd
CY2022Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1717000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	924000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	763000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	234000	usd
CY2022Q2	us-gaap	Inventory Gross InventoryGross	3262000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	808000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	846000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2064000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2416000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	80000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2321616	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	146000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.37
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	46500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	107750	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.76
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2313366	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.69
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	46500	shares
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	79000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	146000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.37
	us-gaap	Proceeds From Customers ProceedsFromCustomers	138000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1112000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7660000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4231000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13569000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	392000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	387000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1215000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1317000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8088000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6967000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black">RECLASSIFICATIONS</span></b></p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"> </p><p style="FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0in; LINE-HEIGHT:normal"><span style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif">Certain comparative figures in the February 28, 2022 condensed consolidated statement of operations have been reclassified to conform to the current period presentation. </span></p>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1112000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7660000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4231000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13569000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	263000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M10D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	360000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	370000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	382000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	201000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1313000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	135000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1178000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Entity Central Index Key EntityCentralIndexKey	0000073290

Files In Submission

Name	View Source	Status
bmra-20230228_def.xml	Edgar Link	unprocessable
0001513162-23-000067-index-headers.html	Edgar Link	pending
0001513162-23-000067-index.html	Edgar Link	pending
0001513162-23-000067.txt	Edgar Link	pending
0001513162-23-000067-xbrl.zip	Edgar Link	pending
bmra-20230228.htm	Edgar Link	pending
bmra-20230228.xsd	Edgar Link	pending
exhibit31_1.htm	Edgar Link	pending
exhibit31_2.htm	Edgar Link	pending
exhibit32_1.htm	Edgar Link	pending
exhibit32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
bmra-20230228_cal.xml	Edgar Link	unprocessable
bmra-20230228_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bmra-20230228_lab.xml	Edgar Link	unprocessable
bmra-20230228_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRA
BIOMERICA INC Stock $bmra

2023 Q2 Form 10-Q Financial Statement

#000151316223000067 Filed on April 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRA BIOMERICA INC Stock $bmra

2023 Q2 Form 10-Q Financial Statement

#000151316223000067 Filed on April 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRA
BIOMERICA INC Stock $bmra